Download Information on Clinical Trials

ONCOLOGY CLINICAL TRIALS OPEN AT THE BON SECOURS HOSPITAL, CORK
BREAST CANCER TRIALS
CADY: Detection of Cardiac Dysfunction in Patients Treated with Trastuzumab for HER2 Positive Breast Cancer.
RESLIENCE TRIAL: A Phase III Randomized, double-blind, placebo-controlled trial
comparing Capecitabine plus Sorafenib versus Capecitabine plus placebo in the
treatment of locally advanced or metastatic HER2-negative breast cancer.
MYOCET & LAPATINIB TRIAL: Phase I/II study of lapatinib plus Myocet TM patients
with HER2+ve metastatic breast cancer following disease progression during, or after,
treatment with trastuzumab and taxanes.
SOLE TRIAL: Study of Letrozole Extension(SOLE study) A phase III trial evaluating the
role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior
adjuvant endocrine therapy for postmenopausal women with hormone-receptor positive,
node positive early stage breast cancer.
TCHL TRIAL: A phase II neo-adjuvant study assessing TCH (Docetaxel, Carboplatin
and Trastuzumab), TCL (Docetaxel, Carboplatin and Lapatinib) and the combination of
TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in ErbB2+ve breast cancer
patients.
EOS TRIAL (European Observation & Survey ) : A 6 month follow up of women treated
for metastatic breast cancer in Europe.
COLORECTAL CANCER TRIALS
SNP TRIAL: Correlation of Single Nucleotide Polymorphism (SNP) profile of domain III
of EGFR to skin toxicity and disease response to treatment with Cetuximab.
GASTROINTESTINAL CANCER TRIALS
SORAFENIB TRIAL: Phase II study of single agent sorafenib in the treatment of
relapsed oesophageal/gastric adenocarcinoma in platinum pre-treated patients.
HAEMATOLOGY TRIALS
LYMPHOMA TRIAL: An open label, randomized phase III trial of Inotuzumab
Ozogamicin administered in combination with Rituximab compared to defined
investigator's choice therapy in subjects with relapsed or refractory CD22 positive NonHodgkin Lymphoma who are not candidates for intensive high dose chemotherapy.